礼来有望在第二季度推出口服肥胖症药物,但尚待美国批准

路透中文
Mar 03
<a href="https://laohu8.com/S/LLY">礼来</a>有望在第二季度推出口服肥胖症药物,但尚待美国批准

路透3月2日 - 礼来LLY.N首席财务官卢卡斯-蒙塔斯(Lucas Montarce)周一表示,该公司正准备在获得美国食品和药物管理局批准后,最早于今年第二季度在美国推出其口服肥胖症新药orforglipron。

"蒙塔斯在 TD Cowen 医疗保健会议上说:"该产品在美国有望最早于第二季度进入市场。

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10